Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  oncolytic virotherapy
Results 1-19 of 19 for your search:
Start Over
Pembrolizumab (MK-3475) With or Without Talimogene Laherparepvec in Unresected Melanoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20110265, NCI-2015-00094, 2014-000185-22, NCT02263508
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Phase: Phase III
Type: Treatment
Age: 18 to 95
Trial IDs: 20120166, NCI-2014-01975, NCT02147951
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 20110264, NCI-2012-03087, NCT01740297
MV-NIS Infected Mesenchymal Stem Cells in Treating Patients with Recurrent Ovarian Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1266, NCI-2014-00016, NCT02068794
Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: VLA 008, NCI-2013-02135, NCT01636882
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 20120324, NCI-2014-00701, NCT02014441
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 20110266, NCI-2015-00229, 2014-001146-13, NCT02211131
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: T14-10682, NCI-2014-02349, NCT02272855
Viral Therapy in Treating Patients with Recurrent Glioblastoma Multiforme
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0671, NCI-2009-01198, MAYO-MC0671, MAYO-06-004440, NCT00390299
Vaccinia Virus in Treating Patients With Solid Tumors
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 06-041, NCI-2011-02461, NCT00574977
Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 09-042, NCI-2010-01930, NCT01071941
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: REO 022, NCI-2012-00474, NCT01274624
Recombinant Oncolytic Poliovirus PVS-RIPO in Treating Patients with Recurrent Grade IV Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00031169, NCI-2013-01899, NS20023, NCT01491893
Intrapleural Measles Virus Therapy in Patients with Malignant Pleural Mesothelioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1023, NCI-2011-03574, 2010UC103, NCT01503177
Viral Therapy in Treating Patient With Liver Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1148, NCI-2012-00890, 11-007114, NCT01628640
Viral Therapy in Treating Patients with Primary, Metastatic, or Mesothelioma-Related Malignant Pleural Effusion
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-169, NCI-2013-00105, GL-ONC1-003/MSKCC, MSKCC-12169, NCT01766739
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0979, NCI-2013-00811, 11-007350, NCT01846091
Oncolytic HSV-1716 in Treating Younger Patients with Refractory or Recurrent High Grade Glioma That Can Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 21
Trial IDs: PBTC-037, NCI-2013-00526, NCT02031965
Viral Protein Production after Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients with Multiple Myeloma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14031, NCI-2014-00643, 14031, 2014C0091, NCI-9603, P9603_A05PAMDREVW01, 9603, NCT02101944
Start Over